生产企业：AskBio Inc., Bayer AG
AB-1002 (umiposgene parvec) is an investigational one-time gene therapy being developed by AskBio Inc., a wholly owned and independently operated subsidiary of Bayer AG, for heart failure. It is administered directly to the heart via antegrade intracoronary artery infusion and is designed to promote production of a modified version (I-1c) of the naturally occurring protein inhibitor-1, blocking the action of protein phosphatase 1 to improve cardiac contractility. It is being evaluated in the Phase 2 GenePHIT trial (NCT#05598333) in patients with non-ischemic heart failure with reduced ejection fraction (HFrEF). Umiposgene parvec has not been approved by any regulatory authority, and its safety and efficacy have not been established.
AB-1002 (umiposgene parvec) is an investigational one-time gene therapy being developed by AskBio Inc., a wholly owned and independently operated subsidiary of Bayer AG, for heart failure. It is administered directly to the heart via antegrade intracoronary artery infusion and is designed to promote production of a modified version (I-1c) of the naturally occurring protein inhibitor-1, blocking the action of protein phosphatase 1 to improve cardiac contractility. It is being evaluated in the Phase 2 GenePHIT trial (NCT#05598333) in patients with non-ischemic heart failure with reduced ejection fraction (HFrEF). Umiposgene parvec has not been approved by any regulatory authority, and its safety and efficacy have not been established.
Umiposgene parvec is an investigational one-time gene therapy administered directly to the heart to promote production of a modified version (I-1c) of the naturally occurring protein inhibitor-1, designed to block the action of protein phosphatase 1, which is linked to heart failure, with the goal of improving cardiac contractility by restoring intracellular calcium signaling.
共 1 项相关疾病
